Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulla Derhaschnig

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
American Heart Journal|April 13, 2004
Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trialUlla Derhaschnig, Christine Pachinger, Bernd Jilma
Thrombosis and Haemostasis|December 4, 2003
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemiaUlla Derhaschnig, Christine Pachinger, Ingrid Schweeger-Exeli, et al.
Orphanet Journal of Rare Diseases|October 8, 2016
Combined integrated protocol/basket trial design for a first-in-human trialUlla Derhaschnig, Jim Gilbert, Ulrich Jäger, et al.
Blood|May 17, 2003
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemiaUlla Derhaschnig, Rosemarie Reiter, Paul Knöbl, et al.
Critical Care Medicine|April 12, 2003
Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemiaUlla Derhaschnig, Thomas Pernerstorfer, Marteen Knechtelsdorfer, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 2, 2007
Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patientsMichael M Hirschl, Andreas Bur, Christian Woisetschlaeger, et al.
Critical Care Medicine|June 12, 2004
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemiaUlla Derhaschnig, Doris Bergmair, Claudia Marsik, et al.
American Journal of Hypertension|April 3, 2003
Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension?Andreas Bur, Harald Herkner, Christian Woisetschläger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 5, 2002
Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients?Ulla Derhaschnig, Harald Kittler, Christian Woisetschläger, et al.
Platelets|July 9, 2010
Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemiaUlla Derhaschnig, Ingrid Schweeger-Exeli, Claudia Marsik, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
American Heart Journal|April 13, 2004
Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trialUlla Derhaschnig, Christine Pachinger, Bernd Jilma
Thrombosis and Haemostasis|December 4, 2003
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemiaUlla Derhaschnig, Christine Pachinger, Ingrid Schweeger-Exeli, et al.
Orphanet Journal of Rare Diseases|October 8, 2016
Combined integrated protocol/basket trial design for a first-in-human trialUlla Derhaschnig, Jim Gilbert, Ulrich Jäger, et al.
Blood|May 17, 2003
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemiaUlla Derhaschnig, Rosemarie Reiter, Paul Knöbl, et al.
Critical Care Medicine|April 12, 2003
Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemiaUlla Derhaschnig, Thomas Pernerstorfer, Marteen Knechtelsdorfer, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 2, 2007
Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patientsMichael M Hirschl, Andreas Bur, Christian Woisetschlaeger, et al.
Critical Care Medicine|June 12, 2004
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemiaUlla Derhaschnig, Doris Bergmair, Claudia Marsik, et al.
American Journal of Hypertension|April 3, 2003
Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension?Andreas Bur, Harald Herkner, Christian Woisetschläger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 5, 2002
Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients?Ulla Derhaschnig, Harald Kittler, Christian Woisetschläger, et al.
Platelets|July 9, 2010
Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemiaUlla Derhaschnig, Ingrid Schweeger-Exeli, Claudia Marsik, et al.
Pageof 6